As one of the most successful, slightly under the radar, pre-IPO “trueicorns” (not fake-icorns), the CEO of Navan, Ariel Cohen, disrupts an old space...
Clinical development is a high-stakes endeavor. Companies invest vast resources, both in terms of time and money, to bring new therapies to market. However,...